Bioventix PLC (LSE: BVXP) is a UK biotech company developing and supplying high-performance antibodies for use in clinical diagnostics. Its antibodies are integral to blood tests for cholesterol, cardiac health, and other key biomarkers. With royalty-based revenue streams from major diagnostic companies, Bioventix benefits from long-term demand for accurate and efficient medical testing.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026


